Protara Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello, everyone, good afternoon. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities.
Our next fireside chat will be with Protara, and joining us here today is CEO, Jesse Shefferman. Jesse, thank you very much for taking the time to join us today. We really appreciate it. I guess just to kick us off, could you perhaps give us a two- or three-minute introduction of your company, your strategy, and your pipeline, and perhaps also since you are taking what seems to be a bit of a differentiated approach compared to many other biotechs out there.
Sure. Thanks, Charles, and thanks to the Guggenheim team for having me on. So Protara is a oncology and rare disease company. We have three programs under development right now, two of which are around our lead program, TARA-002. We'll get a little more detail on that in a bit.
But you talked about what is our differentiated approach. We are really good
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
